<DOC>
	<DOCNO>NCT02639351</DOCNO>
	<brief_summary>Dosage-Escalation Study Evaluate Safety Immunogenicity Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Healthy Adults ( 18-45 year age ) .</brief_summary>
	<brief_title>Safety Immunogenicity Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>1 . Male female individual 18 45 year age day inform consent 2 . Healthy volunteer good physical mental health status , determine basis medical history , physical examination result screen test judge investigator 3 . Individuals voluntarily give write informed consent nature study explain accord local regulatory requirement , prior study entry 4 . Individuals comply study procedure include followup 5 . Individuals able understand , read write German language 6 . Females childbearing potential use effective birth control method intend use least 30 day study vaccination . 1 . Progressive , unstable uncontrolled clinical condition 2 . Hypersensitivity , include allergy , component vaccine , medicinal product medical equipment whose use foreseen study 3 . Clinical condition represent contraindication intramuscular vaccination blood draw 4 . Abnormal function immune system 5 . Received immunoglobulin blood product within 180 day prior inform consent 6 . Received investigational nonregistered medicinal product within 30 day prior informed consent intend participate another clinical study time conduct study 7 . Vulnerable subject ( e.g . person keep detention ) , study personnel immediate family household member study personnel , subject legal incapacity limited legal capacity 8 . Any relevant deviation laboratory parameter screen judge investigator 9 . Previously receive vaccine include MenC antigen 10 . Previously suspect confirmed disease cause N. meningitides 11 . Had household contact and/or intimate exposure individual culture prove MenC 12 . A positive serum urine pregnancy test prior study vaccine administration currently lactate . 13 . A positive drugsofabuse test prior study vaccine administration ; 14 . Received vaccine within 30 day prior enrolment study plan receive vaccine within 30 day administration study vaccine 15 . Any condition , opinion investigator , might interfere result study pose additional risk subject due participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>